AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

OPK · NASDAQ · Medical - Diagnostics & Research

OPKO Health (OPK)

Runs BioReference diagnostics alongside Rayaldee and NGENLA economics.

$1.69

vs last close−0.04 (−2.31%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	179	182	174	182	174	184	150	157	152	148	124	164
Cost of revenue	131	137	132	131	134	99	127	127	121	103	97	84
Gross profit	48	45	42	52	40	85	23	30	30	45	27	80
	112	114	114	113	26	118	90	90	84	83	78	87
Research & development	19	19	22	24	29	30	31	30	30	33	29	33
	72	73	70	69	98	67	59	60	54	51	49	53
General & administrative	0	0	0	0	0	0	0	0	0	0	0	53
Other expenses	20	21	21	20	−101	20	0	0	0	0	0	1
Operating income	−64	−69	−71	−62	14	−33	−67	−60	−54	−38	−51	−7
	−14	−3	−12	51	34	68	−6	−103	95	−9	−10	−6
Interest income	1	1	1	0	3	4	5	3	3	4	3	3
Interest expense	3	3	8	8	17	14	15	70	11	11	11	11
Other non-operating income	11	0	4	−59	−52	−82	−9	32	−106	−3	−1	0
Income before tax	−78	−73	−83	−11	48	35	−73	−163	41	−47	−61	−13
Income tax expense	6	−6	−1	0	24	21	−6	−14	20	−16	−6	−5
Net income from continuing operations	−84	−66	−82	−10	25	14	−68	−148	22	−31	−55	−8
Other adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Net income	−84	−66	−82	−10	25	14	−68	−148	22	−31	−55	−8
EPS, basic	−$0.11	−$0.09	−$0.12	−$0.01	$0.04	$0.02	−$0.10	−$0.19	$0.03	−$0.04	−$0.07	−$0.01
EPS, diluted	−$0.11	−$0.09	−$0.12	−$0.01	$0.03	$0.02	−$0.10	−$0.19	$0.03	−$0.04	−$0.07	−$0.01
Weighted average shares, basic	752	752	707	697	695	694	672	788	777	766	759	755
Weighted average shares, diluted	752	752	707	697	696	694	672	788	780	766	759	755
EBITDA	−49	−43	−50	22	90	73	−34	−69	76	−13	−28	12
Depreciation & amortization	26	26	26	24	24	24	23	23	23	22	22	19
EBIT	−75	−69	−75	−2	66	49	−58	−92	53	−36	−50	−7